Introduction: Everolimus is approved for advanced pancreatic neuroendocrine tumors (pNETs).
Aim(s): To evaluate the effect of cumulative dose (CD) on survival in patients (pts) treated with everolimus for advanced pNETs.
Materials and methods: Twelve pts with advanced pNETs were treated with everolimus. Pts were stratified into two groups with CD<1500 mg (Group A) v. CD≥1500 mg (Group B). ROC curve analysis was performed to determine the 1500 mg cut-off value. Overall survival (OS) was estimated using Kaplan-Meier method.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Rossana Berardi
, Torniai M
, Onofri A
, Partelli S
, Guglielmi S
, Gucciardino C
, Savini A
, Ferretti B
, Enrica T
, Giustini L
, Falconi M
, Cascinu S
To read results and conclusion, please login ...
Further abstracts you may be interested in